Disc Medicine

Disc Medicine is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2017, the company focuses on discovering and developing novel therapies for patients with serious hematologic diseases. It specializes in red blood cell biology, targeting key biological pathways like heme biosynthesis and iron homeostasis to address various blood disorders. The company's product pipeline includes several candidates in clinical and preclinical stages. Notable products include Bitopertin for treating erythropoietic porphyrias, DISC-0974 for anemia related to myelofibrosis and chronic kidney disease, and DISC-3405, which is in phase 1 development for polycythemia vera. Additionally, DISC-0998 is a preclinical program aimed at treating anemia associated with inflammatory diseases. Disc Medicine is dedicated to transforming the lives of patients with hematologic disorders by advancing scientific discoveries into effective therapies. The company emphasizes innovation and scientific rigor, with a team of experienced professionals committed to improving patient outcomes in underserved populations.